Although no specific cutoff value has been established for an elevated Ki67 proliferation index, the 2021 WHO classification of CNS tumors indicates that patients with “higher Ki67 (MIB1) index values” and/or atypical features should be considered for aRT [1]. This evidence concerns the gene MKI67 and central nervous system neoplasm.